🚨 New Breakthrough in Type 2 Diabetes Care! 💊🧬

The ACHIEVE-1 trial shows that Orforglipron, a once-daily oral, nonpeptide GLP-1 receptor agonist, delivers significant reductions in HbA1c and body weight—without injections and with minimal restrictions! 🌍📉

👨‍⚕️ 559 patients across 5 countries

⏱️ 40 weeks, 3 dosing arms (3, 12, 36 mg)

📊 HbA1c ↓ by up to 1.48%, weight ↓ up to 7.6%

✅ No severe hypoglycemia

📌 Mild GI side effects during dose titration

This is a potential gamechanger for early T2DM care—simple, effective, and patient-friendly. 🚀

#Type2Diabetes #GLP1 #Orforglipron #Endocrinology #ClinicalTrials #PrecisionMedicine #Innovation #NEJM #ACHIEVE1 #OralTherapeutics 💥